UMC 0256 Share Price
RM0.30
klse: UMedic Group Berhad
Stock Information
Board : Ace
Shariah : Non-Shariah Compliant
Sector : Hospital or Centre Healthcare Products
Address: PMT 790, Jalan Cassia Selatan 5/2, Taman Perindustrian Batu, Kawan, 14110 Bandar Cassia, Penang
Contact: +604-5899676
Website: https://www.umedic.com.my/
Stock Background
UMediC Group Berhad develops, manufactures, markets, and distributes medical devices. The company operates nursing homes and healthcare centers; markets and distributes laboratory equipment and consumables; and provides after-sales services. In addition, the company provides clinical training on equipment, planned preventive maintenance, installations, equipment pre-checks, equipment servicing and repair, 24/7 emergency call-out, unlimited break down call, and spare parts procurement.
Profit Analysis: UMC 0256
|
Result
Quarter Report History
| Date | Revenue,k | PBT,k | Net Profit,k |
|---|---|---|---|
| 22/06/26 | 12,431 | 2,255 | 1,904 |
| 09/03/26 | 13,405 | 2,653 | 2,001 |
| 08/12/25 | 14,162 | 2,287 | 1,779 |
| 11/09/25 | 12,290 | 3,545 | 2,493 |
| 05/06/25 | 11,640 | 2,412 | 1,904 |
| 11/03/25 | 11,579 | 2,463 | 1,891 |
| 04/12/24 | 13,055 | 2,431 | 1,845 |
| 04/09/24 | 14,876 | 3,799 | 3,035 |
| 10/06/24 | 11,690 | 2,272 | 1,583 |
| 11/03/24 | 13,480 | 3,947 | 2,480 |
| 04/12/23 | 14,524 | 2,626 | 1,889 |
| 12/09/23 | 12,015 | 4,499 | 3,371 |
Fundamental
Fundamental Analysis
| Last 4 Quarter Revenue (RM’000) | 52 |
|---|---|
| Last 4 Quarter Net Profit (RM’000) | 8,709 |
| Last 4 Quarter EPS (sen) | 2.2 |
| Last 4 Quarter PER | 12.88 |
| Last 4 Quarter Dividend (sen) | – |
| Last 4 Quarter Dividend Yield (%) | 0.00 |
| Net Tangible Assets (RM) | 2143.00 |
| Goodwill (RM) | 287 |
| Cash (RM’000) | 16,640 |
| Debt (RM’000) | 6,530 |
| Total Debt (RM’000) | 14,840 |
| Net Assets (RM’000) | 83,900 |
| Current Ratio | 9.13 |
| Quick Ratio | 5.85 |
| Cash Ratio | 2.86 |
Technical
Technical Analysis
| MACD (26 vs 12) | -4.918 |
|---|---|
| Exponential Moving Average 5 | 0.307 |
| Exponential Moving Average 20 | 0.304 |
| Exponential Moving Average 90 | 0.313 |
| Relative Strength Index 14 | 0.53 |
| Stochastic %D 3 | 0.50 |
| Stochastic %K 14 | 0.50 |
5 reviews for UMC 0256
Only logged in customers who have purchased this product may leave a review.
-
BNASTRA 7195 ★★★★★RM2.14 - PETRONM 3042 ★★★★★RM3.44
- CMSB 2852 ★★★★★RM1.00
- SUNREIT 5176 ★★★★★RM2.23
Salary Proof
BURSA MALAYSIA –
PBT of the Group decreased by approximately RM0.29 million or 2.23% from approximately RM12.93 million in the previous financial year to approximately RM12.64 million in the current financial year ended 31 July 2024. The PBT decreased was mainly due to an increase in administrative and other expenses, mainly attributable to transfer listing expenses. Moving Forward, to strengthen our position in the medical industry, the Group established two new subsidiaries Akiteck, launched on 20 May 2024 to design, assemble, and distribute medical moulting solutions, and Ateria Medika, focused on importing, exporting, and servicing medical devices. These additions align with the Group’s strategy to expand its portfolio, offering a wider range of medical devices to meet growing demand and boost its industry presence.
BURSA MALAYSIA –
The PBT of our Group increased by approximately RM4.45 million or 52.46% from approximately RM8.48 million in the previous financial year to approximately RM12.93 million in the current financial year. The higher PBT was contributed by the higher interest income, lower administrative and other expenses as well as lower finance costs. Moving ahead, our Group will continue to expand our current production capacity to gain higher revenues and profitability. We will utilise the proceeds raised from our listing to construct new factory building which is located adjacent to our existing office and factory building in Batu Kawan, Penang. We will set up new marketing and distribution offices each in Kuala Lumpur and Johor Bahru. We will continue to expand our manufacturing segment by developing and commercialising new products under our own brand. We also aim to develop new brand distribution channels to grow our marketing and distribution channel.
BURSA MALAYSIA –
The Group’s revenue for current quarter under review increased by 52.63% to RM11.31 million from RM7.41 million achieved in the preceding quarter. The increase was mainly due to stronger demand from both public and private hospitals as well as healthcare service providers within the marketing and distribution segment, especially on the medical devices and consumables. In addition, there was also an increase in the sale of HydroX series prefilled humidifiers and AirdroX series inhaler spacers. The Group’s PBT for current quarter under review increased by 650% to RM2.25 million from RM0.30 million achieved in the preceding quarter.
BURSA MALAYSIA –
Our Group generated a profit before taxation of RM8.48 million in FYE 2022, a 29.42% increase from RM6.55 million in FYE 2021. Moving ahead, our Group will continue to expand our current production capacity to gain higher revenues and profitability. To achieve this, we will utilise the proceeds raised from our listing to construct new factory building which is located adjacent to our existing office and factory building in Batu Kawan, Penang. We will set up new marketing and distribution offices each in Kuala Lumpur and Johor Bahru as a showroom for our products to showcase and demonstrate the functionality of our products as well as to outreach to more potential customers. We will continue to expand our manufacturing segment by developing and commercialising new products under our own brand. We also aim to develop new brand distribution channels to grow our marketing and distribution channel.
BURSA MALAYSIA –
The Group’s revenue for current quarter under review increased by 17.10% to RM50.74 million from RM43.33 million achieved in the preceding quarter. The increase was mainly due to stronger demand from both public and private hospitals as well as healthcare service providers within the marketing and distribution segment, especially on the medical devices and consumables. There was also an increase in the sale of HydroX series prefilled humidifiers and the Group has also commercialised AirdroX series inhaler spacers during the current quarter. The Group’s PBT for current quarter under review increased by 3.67% to RM8.48 million from RM8.18 million achieved in the preceding quarter.